Nevro Q4 2024 Earnings Report
Key Takeaways
Nevro's worldwide revenue for Q4 2024 was $105.5 million, a 9.1% decrease compared to Q4 2023. The company reported a net loss from operations of $51.4 million. Adjusted EBITDA was negative $5.2 million. The company launched HFX iQ™ with HFX AdaptivAI™ and the HFX iQ SCS system in select European countries during the quarter.
Worldwide revenue decreased by 9.1% to $105.5 million compared to the fourth quarter of 2023.
U.S. revenue decreased by 9.9% to $91.4 million, with permanent implant procedures down by 7.0% and trial procedures down by approximately 14.2%.
Net loss from operations was $51.4 million, which includes a $38.2 million goodwill impairment charge.
Adjusted EBITDA was negative $5.2 million, compared to positive $8.4 million in the fourth quarter of 2023.
Nevro
Nevro
Nevro Revenue by Geographic Location
Forward Guidance
Given the pending acquisition of Nevro by Globus Medical, Nevro is not issuing full-year 2025 guidance, nor is the company holding an earnings conference call and webcast in connection with reporting its fourth-quarter and full-year 2024 financial results.